Vitality Watch

Dossier clinicaltrials trial early 06-aug-2026
Small or early-phase human trial or pilot study

NVTIA® Ergothioneine for Healthy Aging and Skin Health

Key claim: A randomized, double-blind, placebo-controlled 12-week trial is testing whether daily NVTIA® ergothioneine improves oxidative-stress and healthy-aging biomarkers, skin elasticity and hydration, and inflammatory markers in healthy adults aged 40–65.

Abstract

This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of NVTIA® Ergothioneine, a branded ergothioneine ingredient, on healthy aging biomarkers and skin health in healthy adults aged 40 to 65 years. Participants will receive either NVTIA® Ergothioneine or a matching placebo once daily for 12 weeks.

The primary objective of this study is to evaluate the effects of NVTIA® Ergothioneine supplementation on biomarkers associated with oxidative stress and healthy aging. Secondary objectives include assessment of skin elasticity, skin hydration, inflammatory biomarkers, and overall safety. The findings of this study are expected to provide clinical evidence supporting the role of NVTIA® Ergothioneine in promoting healthy aging and maintaining skin health.

Why this matters

A randomized, double-blind, placebo-controlled 12-week trial is testing whether daily NVTIA® ergothioneine improves oxidative-stress and healthy-aging biomarkers, skin elasticity and hydration, and inflammatory markers in healthy adults aged 40–65.

Source

Link

Briefing card

NVTIA® Ergothioneine for Healthy Aging and Skin Health
Stage: trial early · clinicaltrials · 06-aug-2026

A randomized, double-blind, placebo-controlled 12-week trial is testing whether daily NVTIA® ergothioneine improves oxidative-stress and healthy-aging biomarkers, skin elasticity and hydration, and inflammatory markers in healthy adults aged 40–65.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT07750002

build build 880 · 2bcef25 · 2026-11-18